Publications



Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.
J Dermatol Sci 2017 Jan 29;85(1):20-26. Epub 2016 Sep 29.
Laboratory of Investigative Dermatology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065 USA.

The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
J Invest Dermatol 2016 Nov 13;136(11):2173-2182. Epub 2016 May 13.
Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA. Electronic address:






Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative.
J Rheumatol 2015 Oct 15;42(10):1767-80. Epub 2015 Jul 15.
From the University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; Department of Medicine, Dermatology Service, St-Luc Hospital; Sacré-Coeur Hospital of Montreal, University of Montreal; Innovaderm Research; Institut de Rhumatologie de Montréal, Montreal; Centre de Recherche du CHU de Québec, Department of Medicine, Laval University, Quebec City, Quebec; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Dermatology, University of Toronto, Toronto; Division of Rheumatology, Western University of Canada, London; Lynde Dermatology, Markham, Ontario; Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.C. Roubille, MD, Rheumatology Research Fellow, University of Montreal Hospital Research Center (Centre de Recherche du CHUM), Notre-Dame Hospital; V. Richer, MD, Dermatology Resident, Department of Medicine, Dermatology Service, St-Luc Hospital; T. Starnino, MD, Rheumatology Resident, Sacré-Coeur Hospital of Montreal, University of Montreal; C. McCourt, MB, BCh, Clinical Fellow in Immunodermatology, Department of Dermatology and Skin Science, University of British Columbia; A. McFarlane, MD, Internal Medicine Resident, Division of Rheumatology, University of Alberta; P. Fleming, MD, Dermatology Resident, Division of Dermatology, University of Toronto; S. Siu, MD, Internal Medicine Resident, Division of Rheumatology, Western University of Canada; J. Kraft, MD, Dermatologist; C. Lynde, MD, Dermatologist, Lynde Dermatology; J. Pope, MD, Professor of Rheumatology, Division of Rheumatology, Western University of Canada; W. Gulliver, MD, Professor of Medicine, Faculty of Medicine, Memorial University of Newfoundland; S. Keeling, MD, Associate Professor of Rheumatology, Division of Rheumatology, University of Alberta; J. Dutz, MD, Professor of Dermatology, Departm


A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
N Engl J Med 2015 Jul;373(2):136-44
From the Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago (K.B.G.); the Department of Dermatology, University of Utah School of Medicine, Salt Lake City (K.C.D.); Innovaderm Research, Montreal (R.B.); the Department of Dermatology, Ludwig-Maximilians-Universität München, Munich (J.C.P.), and the Dermatologikum Hamburg, Hamburg (K.R.) - both in Germany; and Janssen Research and Development, Spring House (Y.W., S.L., Y.-K.S., P.S., B.R.), and the Department of Dermatology, University of Pennsylvania, Philadelphia (B.R.) - both in Pennsylvania.


Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers.
Ann Rheum Dis 2015 May 9;74(5):e34. Epub 2015 Mar 9.
Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut de Rhumatologie de Montréal, Montreal, Quebec, Canada.




OF